To continue getting breaking news and the full stories from The Boston Globe, subscribe today.

The Boston Globe

Business

Boston.com

MASS. MOVERS

Doubts arise on Idenix’s hepatitis drug

  April 05, 2012

Idenix Pharmaceuticals Inc. stock sank as investors speculated the Cambridge company’s experimental hepatitis C treatment may face development hurdles. Idenix dropped 12 percent to $9 at 4 p.m. New York time, for the biggest one-day decline since Aug. 9. The shares of the Cambridge, Massachusetts-based company had tripled in the 12 months before today as larger drugmakers made a series of takeovers of companies developing hepatitis C therapies.

Stay with the story. Get full access to BostonGlobe.com for just 99¢

Unlimited access to BostonGlobe.com for only 99¢ for the first 4 weeks. You can cancel at any time.

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
Get started today

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help